Management expects growth momentum to slow to low-single digits in Q4 due to uncertainties around NIH funding and tariffs. Adjusted operating margin is projected to be 100 to 150 basis points lower in ...

Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...

Rachel King is a trailblazer in biotech, a venture capitalist turned co-founder and CEO, now turned industry leader. As CEO of the Biotechnology Innovation Organization (BIO), King has focused in ...